Cargando…
Prognostic Value of the Glasgow Prognostic Score on Overall Survival in patients with Advanced Non-Small Cell Lung Cancer
Background: Findings from previous studies regarding the association between the Glasgow Prognostic Score (GPS) and overall survival (OS) of patients with advanced non-small cell lung cancer (NSCLC) were limited. This study aimed to investigate the prognostic value of GPS in patients with advanced N...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7974889/ https://www.ncbi.nlm.nih.gov/pubmed/33758615 http://dx.doi.org/10.7150/jca.52215 |
_version_ | 1783666943818989568 |
---|---|
author | Pan, Mingmei Zhao, Yun He, Jianbo Wu, Huanqiong Pan, Yujia Yu, Qitao Zhou, Shaozhang |
author_facet | Pan, Mingmei Zhao, Yun He, Jianbo Wu, Huanqiong Pan, Yujia Yu, Qitao Zhou, Shaozhang |
author_sort | Pan, Mingmei |
collection | PubMed |
description | Background: Findings from previous studies regarding the association between the Glasgow Prognostic Score (GPS) and overall survival (OS) of patients with advanced non-small cell lung cancer (NSCLC) were limited. This study aimed to investigate the prognostic value of GPS in patients with advanced NSCLC after adjusting for potential confounding factors. Methods: A retrospective cohort study was conducted in 494 patients with advanced NSCLC between 2009 and 2019. Clinicopathological characteristics (including GPS) were analyzed to determine predictors of OS using univariate and multivariate Cox proportional hazards models. Survival curves were estimated using the Kaplan-Meier method. Results: Of the enrolled patients with advanced NSCLC, 66.46% were men and 53.85% were aged <60 years. The percentages of GPS scores of 0, 1, and 2 were 36.44%, 36.03%, and 27.53%, respectively. The median OS of the GPS 0, 1, and 2 groups were 23.27, 14.37, and 10.27 months, respectively (log-rank P <0.0001). A higher GPS was independently associated with an increased risk of death (P for trend = 0.0004) after full adjustment for potential confounders. The risk of death increased by 77% in the GPS 1 group (hazard ratio [HR]=1.77, 95% confidence interval [CI]=1.22-2.57, P=0.0027) and 109% in the GPS 2 group (HR=2.09, 95%CI=1.36-3.22, P=0.0008) compared with the GPS 0 group after adjustment. We did not find significant heterogeneity among the analyzed subgroups apart from sex (P interaction=0.017). Conclusion: High pretreatment GPS is independently associated with worse OS in patients with advanced NSCLC. GPS should be considered in patient counseling and decision-making and needs to be further validated by large-cohort and prospective studies. |
format | Online Article Text |
id | pubmed-7974889 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-79748892021-03-22 Prognostic Value of the Glasgow Prognostic Score on Overall Survival in patients with Advanced Non-Small Cell Lung Cancer Pan, Mingmei Zhao, Yun He, Jianbo Wu, Huanqiong Pan, Yujia Yu, Qitao Zhou, Shaozhang J Cancer Research Paper Background: Findings from previous studies regarding the association between the Glasgow Prognostic Score (GPS) and overall survival (OS) of patients with advanced non-small cell lung cancer (NSCLC) were limited. This study aimed to investigate the prognostic value of GPS in patients with advanced NSCLC after adjusting for potential confounding factors. Methods: A retrospective cohort study was conducted in 494 patients with advanced NSCLC between 2009 and 2019. Clinicopathological characteristics (including GPS) were analyzed to determine predictors of OS using univariate and multivariate Cox proportional hazards models. Survival curves were estimated using the Kaplan-Meier method. Results: Of the enrolled patients with advanced NSCLC, 66.46% were men and 53.85% were aged <60 years. The percentages of GPS scores of 0, 1, and 2 were 36.44%, 36.03%, and 27.53%, respectively. The median OS of the GPS 0, 1, and 2 groups were 23.27, 14.37, and 10.27 months, respectively (log-rank P <0.0001). A higher GPS was independently associated with an increased risk of death (P for trend = 0.0004) after full adjustment for potential confounders. The risk of death increased by 77% in the GPS 1 group (hazard ratio [HR]=1.77, 95% confidence interval [CI]=1.22-2.57, P=0.0027) and 109% in the GPS 2 group (HR=2.09, 95%CI=1.36-3.22, P=0.0008) compared with the GPS 0 group after adjustment. We did not find significant heterogeneity among the analyzed subgroups apart from sex (P interaction=0.017). Conclusion: High pretreatment GPS is independently associated with worse OS in patients with advanced NSCLC. GPS should be considered in patient counseling and decision-making and needs to be further validated by large-cohort and prospective studies. Ivyspring International Publisher 2021-03-01 /pmc/articles/PMC7974889/ /pubmed/33758615 http://dx.doi.org/10.7150/jca.52215 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Pan, Mingmei Zhao, Yun He, Jianbo Wu, Huanqiong Pan, Yujia Yu, Qitao Zhou, Shaozhang Prognostic Value of the Glasgow Prognostic Score on Overall Survival in patients with Advanced Non-Small Cell Lung Cancer |
title | Prognostic Value of the Glasgow Prognostic Score on Overall Survival in patients with Advanced Non-Small Cell Lung Cancer |
title_full | Prognostic Value of the Glasgow Prognostic Score on Overall Survival in patients with Advanced Non-Small Cell Lung Cancer |
title_fullStr | Prognostic Value of the Glasgow Prognostic Score on Overall Survival in patients with Advanced Non-Small Cell Lung Cancer |
title_full_unstemmed | Prognostic Value of the Glasgow Prognostic Score on Overall Survival in patients with Advanced Non-Small Cell Lung Cancer |
title_short | Prognostic Value of the Glasgow Prognostic Score on Overall Survival in patients with Advanced Non-Small Cell Lung Cancer |
title_sort | prognostic value of the glasgow prognostic score on overall survival in patients with advanced non-small cell lung cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7974889/ https://www.ncbi.nlm.nih.gov/pubmed/33758615 http://dx.doi.org/10.7150/jca.52215 |
work_keys_str_mv | AT panmingmei prognosticvalueoftheglasgowprognosticscoreonoverallsurvivalinpatientswithadvancednonsmallcelllungcancer AT zhaoyun prognosticvalueoftheglasgowprognosticscoreonoverallsurvivalinpatientswithadvancednonsmallcelllungcancer AT hejianbo prognosticvalueoftheglasgowprognosticscoreonoverallsurvivalinpatientswithadvancednonsmallcelllungcancer AT wuhuanqiong prognosticvalueoftheglasgowprognosticscoreonoverallsurvivalinpatientswithadvancednonsmallcelllungcancer AT panyujia prognosticvalueoftheglasgowprognosticscoreonoverallsurvivalinpatientswithadvancednonsmallcelllungcancer AT yuqitao prognosticvalueoftheglasgowprognosticscoreonoverallsurvivalinpatientswithadvancednonsmallcelllungcancer AT zhoushaozhang prognosticvalueoftheglasgowprognosticscoreonoverallsurvivalinpatientswithadvancednonsmallcelllungcancer |